Camp4 Therapeutics Corporation

CAMP4 Therapeutics Preprints Pioneering Study on Regulatory RNA Profiling and Gene Upregulation

Calamos Brings Award-Winning Autocallable Income ETF Strategy to Global Investors with Launch of World's First Autocallable UCITS ETF

CAMP4 Appoints Michael MacLean to its Board of Directors

CAMP4 to Participate in Upcoming Investor Conferences

CAMP4 Reports Full Year 2025 Financial Results and Corporate Highlights